ANAVEX LIFE SCIENCES CORP
NASDAQ: AVXL (Anavex Life Sciences Corp.)
Last update: 5 minutes ago3.86
0.40 (11.56%)
| Previous Close | 3.46 |
| Open | 3.54 |
| Volume | 3,738,789 |
| Avg. Volume (3M) | 2,106,623 |
| Market Cap | 344,883,680 |
| Price / Earnings (Forward) | 3.85 |
| Price / Book | 2.89 |
| 52 Weeks Range | |
| Earnings Date | 9 Feb 2026 |
| Diluted EPS (TTM) | -0.560 |
| Current Ratio (MRQ) | 6.74 |
| Operating Cash Flow (TTM) | -29.81 M |
| Levered Free Cash Flow (TTM) | -13.69 M |
| Return on Assets (TTM) | -25.44% |
| Return on Equity (TTM) | -40.17% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Anavex Life Sciences Corp. | Bearish | Bearish |
AIStockmoo Score
| Analyst Consensus | 3.0 |
| Insider Activity | NA |
| Price Volatility | 3.0 |
| Technical Moving Averages | -1.5 |
| Technical Oscillators | -2.5 |
| Average | 0.50 |
|
Anavex Life Sciences Corp is a clinical-stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system diseases with high unmet need. It analyzes genomic data from clinical studies to identify biomarkers, which are further used in the analysis of clinical trials. The company's focus is on developing treatments for Alzheimer’s disease, Parkinson’s disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders. Its various therapeutic candidates in different stages of development include Anavex 2-73 (Blacamesine), Anavex 3-71 (AF710B), Anavex 1-41, and Anavex 1066. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 3.33% |
| % Held by Institutions | 37.67% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Blackrock, Inc. | 30 Sep 2025 | 7,188,269 |
| Vanguard Group Inc | 30 Sep 2025 | 5,104,510 |
| State Street Corp | 30 Sep 2025 | 3,287,118 |
| Geode Capital Management, Llc | 30 Sep 2025 | 2,027,327 |
| Two Sigma Investments, Lp | 30 Sep 2025 | 1,036,954 |
| Nwam Llc | 30 Sep 2025 | 874,283 |
| Northern Trust Corp | 30 Sep 2025 | 773,012 |
| Two Sigma Advisers, Lp | 30 Sep 2025 | 758,500 |
| Charles Schwab Investment Management Inc | 30 Sep 2025 | 717,378 |
| Susquehanna International Group, Llp | 30 Sep 2025 | 603,818 |
| Morgan Stanley | 30 Sep 2025 | 560,148 |
| Lpl Financial Llc | 30 Sep 2025 | 534,319 |
| Ubs Group Ag | 30 Sep 2025 | 491,977 |
| Private Advisor Group, Llc | 30 Sep 2025 | 455,125 |
| Summit Financial, Llc | 30 Sep 2025 | 444,271 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 24.00 (D. Boral Capital, 521.76%) | Buy |
| Median | 22.00 (469.95%) | |
| Low | 20.00 (HC Wainwright & Co., 418.14%) | Buy |
| Average | 22.00 (469.95%) | |
| Total | 2 Buy | |
| Avg. Price @ Call | 3.73 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| D. Boral Capital | 26 Nov 2025 | 24.00 (521.76%) | Buy | 3.86 |
| 14 Nov 2025 | 24.00 (521.76%) | Buy | 3.65 | |
| HC Wainwright & Co. | 19 Nov 2025 | 20.00 (418.13%) | Buy | 3.60 |
| 07 Oct 2025 | 42.00 (988.08%) | Buy | 9.78 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |